Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells.

@article{Kim2009RapamycinEO,
  title={Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells.},
  author={So Hee Kim and Kim L Zukowski and Raymond F. Novak},
  journal={Anticancer research},
  year={2009},
  volume={29 4},
  pages={1143-50}
}
Rapamycin, an inhibitor of mTOR, is in clinical trials for treatment of cancer. Rapamycin resistance has been reported in human breast epithelial tumor cells. Rapamycin effects on mTOR signaling and resistance were examined using benign, premalignant and tumor human breast epithelial cells. Rapamycin inhibition of cell proliferation, the cell cycle and mTOR signaling, including p70S6 and S6RP phosphorylation, was most effective in benign (MCF10A) and premalignant (MCF10AT; MCF10ATG3B) human… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Nutritional and regulatory role of branched-chain amino acids in lactation.

Frontiers in bioscience • 2012
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Cancer statistics, 2004.

CA: a cancer journal for clinicians • 2004

Determinants of rapamycin sensitivity in breast cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2004

Similar Papers

Loading similar papers…